Valuation
- Market cap
- 1,000
- Revenue TTM
- $0
- Net income TTM
- $-1,020,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 77,100
- Avg volume
- 36,384
- Day's range
- $0.00 – $0.00
- Shares out
- 11,770,000
- Stochastic %K
- 50%
- Beta
- -0.48
- Analysts
- —
- Price target
- —
Company profile
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 818 597 7552
- Website
- https://www.rebus-corp.com
- Address
- 2629 Townsgate Road, Suite 215, Westlake Village, United States
Latest news
No headlines yet.
